The pandemic of human immunodeficiency virus type one (HIV-1), the major etiologic agent of acquired immunodeficiency disease (AIDS), has led to over 33 million people living with the virus, among which 18 million are women and children. Until now, there is neither an effective vaccine nor a therapeutic cure despite over 30 years of efforts. Although the Thai RV144 vaccine trial has demonstrated an efficacy of 31.2%, an effective vaccine will likely rely on a breakthrough discovery of immunogens to elicit broadly reactive neutralizing antibodies, which may take years to achieve. Therefore, there is an urgency of exploring other prophylactic strategies. Recently, antiretroviral treatment as prevention is an exciting area of progress in HIV-1 research. Although effective, the implementation of such strategy faces great financial, political and social challenges in heavily affected regions such as developing countries where drug resistant viruses have already been found with growing incidence. Activating latently infected cells for therapeutic cure is another area of challenge. Since it is greatly difficult to eradicate HIV-1 after the establishment of viral latency, it is necessary to investigate strategies that may close the door to HIV-1. Here, we review studies on non-vaccine strategies in targeting viral entry, which may have critical implications for HIV-1 prevention.
INTRODUCTION
Human immunodeficiency virus type one (HIV-1) is the major etiologic agent of acquired immunodeficiency disease (AIDS) (Barre-Sinoussi et al., 1983) . Currently, the estimated number of people living with HIV-1 is about 33.3 million, among which 18.4 million are women and children. Since its inception, HIV-1 prevalence has brought a ponderous burden to human health and world-wide economic development, especially in the developing countries (UNAIDS., 2010) . A cheap, safe and effective prophylactic measure, such as vaccine, remains the first priority of HIV/AIDS research. However, the failure of a leading T cell-based AIDS vaccine MRKAd5 in a Phase 2b clinical trial has raised doubts about the feasibility of such types of candidates (Buchbinder et al., 2008) . Recently, although the Thai RV144 clinical trial demonstrated an efficacy of 31.2% (Rerks-Ngarm et al., 2009) , it remains unclear when an effective vaccine will be made available for HIV-1 prevention. Other prophylactic strategies, therefore, should be explored urgently as well.
The life cycle of HIV-1 can simply be divided into two major phases: entry phase and post-entry phase. The post-entry phase includes reverse transcription, integration, viral RNA and protein synthesis, packaging and budding. Highly active antiretroviral therapy (HAART), which has been successfully used in reducing AIDS-related deaths in the past 16 years, is usually composed of three antiviral drugs including reverse transcriptase inhibitors (RTI) and protease inhibitors (PI) targeting the post-entry phase (Hammer et al., 1996; Lu et al., 2012) . Although successful, there are drug-resistant viruses found against these viral inhibitors (Boden et al., 1999; Luo et al., 2009) . Current HAART also fails to eradicate HIV-1 from infected people. Viral entry phase has, therefore, become an attractive target for the development of preventive and curative strategies against HIV-1 infection.
The entry of HIV-1 into susceptible cells can be dissected into at least three continuous steps ( Fig. 1 ): (i) HIV-1 initiates its infection by binding of viral envelope protein (Env) to the cluster of differentiation 4 (CD4) receptor, followed by a conformational change in viral glycoprotein 120 (gp120). (ii) As a result, a hidden binding site within the variable loop 3 (V3) on gp120 is exposed, allowing subsequent binding to one of the co-receptors, either C-C chemokine receptor type 5 (CCR5) or C-X-C chemokine receptor type 4 (CXCR4). (iii) A further conformational remodeling of gp120 induces a gp41 conformation transition which allows its hydrophobic N-terminus to penetrate host cell, mediates membrane fusion between virus and cell, and release viral RNAs and enzymes into cells (Eckert and Kim, 2001; Pierson and Doms, 2003) . Each of these steps has provided a target to develop non-vaccine antiviral strategies including neutralizing antibodies, synthesized peptides and polymers, small molecule inhibitors or gene therapies (Fig. 1) . This review will discuss recent progresses of these non-vaccine strategies in targeting the HIV-1 entry phase.
PASSIVE IMMUNIZATION USING NEUTRALIZING ANTIBODIES
Significant progresses have been made in recent years on the identification of broadly-reactive neutralizing antibodies (bnAbs) targeting to viral Env, CD4 or co-receptors using various techniques (Fig. 1) . Critically, passive immunization using these bnAbs has consistently resulted in protection against SHIV/HIV-1 in pre-clinical and clinical trials, suggesting the essential role of bnAbs in antibody-based prophylaxis. Till now, however, these kinds of bnAbs still cannot be elicited in vivo by active vaccination. Although these bnAbs cannot be orally delivered due to the uptake and metabolism issues, improved passive immunization to produce long-lasting bnAbs after delivered by either purified proteins or gene-encoded vectors is likely an attractive approach for HIV-1 prevention. The current understandings on these bnAbs are summarized as follows.
Monoclonal antibody b12 is a recombinant product selected by a phage display technology from a long-term nonprogressor (LTNP) (Barbas et al., 1992) . It targets the critical CD4-binding site of gp120 and exhibits a broad spectrum of anti-HIV-1 activity in vitro (Burton et al., 1994; Roben et al., 1994) . Crystal structures of b12 and b12-bound gp120 indicate that the long complementary determining region (CDR) H3 of b12 protrudes into the recessed CD4-binding site of gp120 and maintains an intact bridging sheet of gp120, which determined its broadly neutralizing activity (Saphire et al., 2001; Chen et al., 2009) . Passive immunization of b12 confers a dose dependent inhibition of HIV-1 infectivity in severe combined immunodeficiency (SCID) mice transplanted with human peripheral blood lymphocytes (hu-PBL) and in vaginally challenged rhesus macaques Veazey et al., 2003) . Resistant viruses to b12 were observed by both in vitro selection and in HIV-1-infected patients (Mo et Duenas-Decamp et al., 2008) . The resistant viruses lost sensitivity to b12 while retaining CD4 for entry, and the mechanism of this viral resistance involved the variations in the b12 contact residues that reside close to the CD4 binding loop (Duenas-Decamp et al., 2008; Wu et al., 2009) . Nabs 2F5 and 4E10 are anti-gp41 monoclonal antibodies generated from HIV-1-seropositive donors with potent and broad anti-HIV-1 activity (Muster et al., 1993; Purtscher et al., 1994) . They directly target the membrane-proximal external region (MPER) of gp41 and abolish viral fusion (Zwick et al., 2001a) . Similar to b12, 2F5 prevents HIV-1 infection of human dendritic cells (DCs) and the DC-mediated HIV-1 transmission to T cells in vitro (Frankel et al., 1998) . Mutations on the recognition epitope of 2F5, ELDKWA, result in neutralization resistance by affecting the binding of 2F5 . Passive immunization of 2F5 confers a delayed seroconversion in a chimpanzee intravenous challenge model (Conley et al., 1996) . Phase 1 clinical trial has confirmed that 2F5 is safe and well tolerated by injection (Armbruster et al., 2002) . Consistent data have been obtained from a phase 2 long-term multiple-dose pharmacokinetics study conducted in HIV-1 infected patients (Joos et al., 2006) . The antibody-dependent cell cytotoxicity (ADCC) induced by 2F5 contributes to the elimination of HIV-1 infected cells (Tudor and Bomsel, 2011) . 4E10 recognizes a linear epitope, NWFDIT, located at the C-terminal of the 2F5 epitope (Stiegler et al., 2001 ). Co-administration of 4E10 and 2F5 results in a synergistic neutralizing effect in vitro (Zwick et al., 2001b) . To note, substitutions in the MPER contributed to the resistance to 4E10 (Gray et al., 2008; Nakamura et al., 2010) . The safety and tolerability of 4E10 for clinical use have also been confirmed by a phase 2 clinical study (Joos et al., 2006) . In rhesus macaques, passive immunization of 4E10 and 2F5 provides protection against intrarectal challenge with SHIV (Hessell et al., 2010) and delays the viral rebound in HIV-1 infected patients . Although promising, the phospholipid binding property of 2F5 and 4E10 compels a more strict safety concern on this autoreactivity issue in future clinical trials (Scherer et al., 2007; Vcelar et al., 2007) .
2G12 is a human IgG1 cross-clade anti-HIV-1 Nab isolated from the blood of HIV-infected individuals but with a higher neutralization efficacy against B-clade isolates . It recognizes an N-linked high-mannose glycan cluster on the surface of gp120 with its unique dimeric structure . 2G12 can form natural dimers that involve a domain swap between two adjacent heavy chains with multivalent binding interface that facilitates binding to its carbohydrates epitope on gp120 (Calarese et al., 2003) . Compared to 2G12 monomer, dimeric 2G12 shows a significant increase in neutralization potency by both in vitro and in vivo assays without selecting for complete HIV-1 escape mutants (West et al., 2009; Luo et al., 2010) . A study shows that 2G12 can effectively protect against SHIV challenge in macaque models even at a low serum concentration (Hessell et al., 2009 ). Moreover, combining with 4E10 and 2F5, 2G12 shows a protective ability to suppress HIV-1 replication in humans despite the selected viral escape mutants (Baba et al., 2000; Trkola et al., 2005) , partially due to its long in vivo half-life (Joos et al., 2006) .
Ibalizumab (5A8, TNX-355, TMB-355) is a humanized monoclonal Nab that targets the domain 2 of the CD4 receptor (Moore et al., 1992) . A detailed epitope mapping study suggests that some residues within domain 1 also contribute to the binding (Song et al., 2010) . Ibalizumab serves as a molecular lock on CD4, which does not interfere with the binding of virion, but it does abort its capability of inducing conformational changes in gp120 through a noncompetitive inhibition manner. After Ibalizumab binding, gp120 is locked into an unfit state for co-receptor interaction Moore et al., 1992) . Ibalizumab and T-20 exhibit a synergistic antiviral activity in vitro (Zhang et al., 2006) . However, passive immunization of Ibalizumab resulted in a transient suppression of SIV replication in macaques, together with anti-Ibalizumab response and resistant viral mutants detected (Reimann et al., 2002) . In clinical phase 1b study, HIV-1 infected patients were intravenously injected with Ibalizumab. Twenty out of 22 patients had a significant reduction in plasma viral load along with resistant viruses retaining CD4 dependency identified (Jacobson et al., 2009) . A further phase 2a study in treatment-experienced subjects indicated that Ibalizumab with an optimized background regimen further reduced plasma viremia compared to a background regimen at week 24 (Norris et al., 2006) , leading to a phase 2b dose optimization study under investigation.
PRO-140 (PA14) is a humanized murine anti-CCR5 monoclonal antibody with potent neutralizing activity against HIV-1 of subtypes A, B, C, E, F at low nanomolar concentrations without preventing chemokine-stimulated CCR5 signaling (Olson et al., 1999; Trkola et al., 2001) . Alanine scanning indicated that PRO-140 recognizes a conformational epitope spanning the N-terminus, extracellular loops 1 and 2 on CCR5. When used in combination with Maraviroc, Vicriviroc and TAK-779, synergistic drug effect was observed as compared to additive effects when combined with reverse transcriptase inhibitors (Murga et al., 2006) . In a phase 1b study, a substantially enhanced mean reduction of viral load was observed in 2 mg/kg and 5 mg/kg groups of PRO-140 as compared with the placebo control. A phase 2a study showed similar results, in which the reduction was durable for 2-3 weeks after PRO-140 administration provided a promise for single dose weekly therapy (Jacobson et al., 2010a) . Moreover, weekly or biweekly subcutaneous administration of PRO-140 resulted in significantly enhanced mean reduction in HIV-1 load in another phase 2a clinical trial (Jacobson et al., 2010b) . These findings revealed a potent and long-lasting antiviral activity of PRO-140 in vivo.
VRC01-like Nabs, including VRC01-03 and VRCPG04, are a new class of human anti-HIV-1 monoclonal Nabs that specifically target CD4-binding site of gp120 with extraordinary neutralization potency and breadth (Wu et al., , 2011 . These Nabs were directly cloned from antigen-specific B cells of a HIV-1 infected individual selected with potent neutralization sera. VRC01, a representative of these Nabs, can neutralize over 90% of circulating HIV-1 isolates tested in vitro. The crystal structure of VRC01 in complex with gp120 shows that by partial mimicry of the CD4 receptor, VRC01 directly contacts with gp120 in the CD4-binding site, where defined as a site of vulnerability for antibody access . Further studies by deep sequencing and crystal structure reveal that VRC01-like Nabs share a similar mode of gp120 recognition though harboring diverged sequences, indicating a common pathway of B cell affinity maturation that highly contributes to the broad neutralization capacity (Scheid et al., 2011; Wu et al., 2011) . As a preliminary study suggests that VRC01 does not have significant reactivity with human antigens, this antibody, therefore, has great potential for in vivo application of passive immunization. To this end, humanized mice are completely protected from HIV-1 infection after vectored-passive immunization of b12 and VRC01 (Balazs et al., 2012) . PG9 and PG16 are two somatically related human Nabs that can neutralize 70%-80% of globally circulating HIV-1 isolates. They were isolated from a HIV-1 (clade A) infected donor, who presents broad and potent neutralizing serum activity as determined by a high-throughput functional assay (Walker et al., 2009) . As compared to b12 and 2G12, PG9 and PG16 exhibit enhanced neutralizing ability against non-clade B viruses, and they have a preference to recognize assembled spike viral rather than monomeric gp120, suggesting potential new epitopes for immunogen design. Both of them contain a long protruding CDR H3 loop penetrating a N-linked glycan shield to variable regions of gp120 (Pancera et al., 2010; McLellan et al., 2011) . This so-called "hammerhead" subdomain is a common structure shared by antibodies that target the highly glycosylated V1V2 region of gp120, and is responsible for the neutralization and binding specificity of these antibodies.
Using the same technique of PG9 and PG16, another new class of PGT human monoclonal Nabs was isolated . Some PGT Nabs have a potency of 10-fold more than PG9, PG16 and VRC01 bnAbs. At concentrations less than 0.1 μg/mL, PGT Nabs are able to neutralize 27% to 50% of viruses tested. They, therefore, could possibly provide protection at relatively low serum concentrations. PGT128, the broadest Nab among this class, interacts with a conserved site of V3 and two glycans of the gp120 subunit, which determines its high binding affinity and wide-ranging specificity . In addition, a recent study reports another HIV-1 gp41 MPER-specific antibody, named 10E8, which neutralizes 98% of viruses tested (Huang et al., 2012) . In contrast to 2F5 and 4E10, 10E8 does not bind phospholipids, is not autoreactive, and binds cell-surface envelope. The structure of 10E8 in complex with the complete MPER reveals a vulnerable site consisted of a narrow stretch of highly conserved gp41-hydrophobic residues and a critical arginine or lysine just before the transmembrane region. These residues are critical for neutralization by testing resistant HIV-1 variants. It, however, remains elusive whether or not HIV-1 vaccines could induce similar bnAbs to this region.
SYNTHESIZED PEPTIDES AND POLYMERS
Recombinant antibody-like peptides, synthesized polymers, modified chemokines and structural mimic oligomers belong to this class of entry inhibitors (Fig. 1) . They inhibit HIV-1 infectivity by distinct mechanisms, but they usually have high potency in common. In this class, the first FDA-approved clinical drug targeting HIV-1 entry, T-20, and other drugs in pipeline are described as follows.
PR0-542 (CD4-IgG2) is a recombinant antibody-like heterotetramer. It mimics the CD4 receptor and competitively binds to the CD4-binding sites on gp120. PRO-542 exerts potent neutralizing activity against the cell-free HIV-1 infection and cell-to-cell virus transmission in vitro (Allaway et al., 1995) . It also protects hu-PBL-SCID mice from HIV-1 challenge (Gauduin et al., 1998) . Co-administration of PRO-542 and T-20 contribute to synergistic inhibition against diverse HIV-1 subtypes . Clinical phase 1/2 studies reveal that PRO-542 is well tolerated by both HIV-1 infected adults and children, and confers sustained reduction in HIV-1 load (Shearer et al., 2000; Jacobson et al., 2004) . These findings support the development of PRO-542 as an approved medication for clinical use.
PR0-2000, a naphthalene sulfonate polymer, blocks both CCR5-and CXCR4-tropic HIV-1 infection ( Fig. 2A) . It binds to the CD4 molecule and competitively inhibits binding of gp120 (Rusconi et al., 1996) . It may also bind to CXCR4 and gp120, suggesting multiple mechanisms of inhibition (Huskens et al., 2009) . In a formulation of microbicide, it protects human female genital tissues against HIV-1 infection (Greenhead et al., 2000) . It also inhibits DC-mediated virus transfer in vitro (Teleshova et al., 2008) . Phase 1 trials of PRO-2000 microbicide gel have revealed its safety and acceptability in healthy women (Smita et al., 2006) . PRO-2000 microbicide gel is also well tolerated by HIV-infected women and men (Mayer et al., 2003; Tabet et al., 2003) . Unfortunately, PRO-2000 gel showed only modest protection among women against HIV-1 in a phase 2/2b study (Abdool Karim et al., 2011) . In a phase 3 randomized clinical trial, HIV-1 negative and sexually active women were randomly assigned into two groups, applying PRO-2000 microbicide gel or placebo gel, respectively, within an hour before sexual activity. HIV-1 incidence was comparable between the two groups. PR0-2000 microbicide gel, therefore, failed to show effectiveness as a woman-controlled prevention method against HIV-1 transmission (McCormack et al., 2010) . RANTES, a β-chemokine ligand, was found to inhibit HIV-1 infection in lymphocytes, which led to the identification of CCR5 as one of the co-receptors for HIV-1 entry (Fig. 2B ) (Deng et al., 1996) . Biologically, RANTES can activate CCR5 signaling pathways that may promote inflammatory effects. To remove these effects, chemical modification of N-terminus result in met-RANTES (Proudfoot et al., 1996) , AOP-RANTES (Simmons et al., 1997) , NNY-RANTES (Mosier et al., 1999) and PSC-RANTES (Fig. 2C) (Pastore et al., 2003) . These RANTES derivatives inhibit HIV-1 infection by inducing CCR5 internalization besides blocking virion binding. PSC-RANTES, in the formulation of microbicide, provides potent protection against SHIV transmission in rhesus macaques . Some mutant viruses have been identified but whether they are resistant to PSC-RANTES remains controversial (Dudley et al., 2009; Nedellec et al., 2010) .
T-20 (DP-178, Fuzeon, Enfuvirtide) is a FDA approved medication targeting the fusion step of HIV-1 entry (Fig. 2D) . It is a synthetic peptide that consists of 36 amino acids spanning the heptad repeat (HR) 2 region of gp41 (Wild et al., 1993) . T-20 directly binds to the central coiled-coil HR1 region and completely inhibits the native HR1-HR2 interaction and the sequential formation of the six-helix bundle structure, a necessary process in membrane fusion (Chen et al., 1995) . It inhibits potently both CCR5-tropic and CXCR4-tropic HIV-1 but not HIV-2 and SIV due to sequence variations (Reeves et al., 2002; Witvrouw et al., 2004) . Clinical T-20 escape viruses result from emergence of mutations in the target sequence on gp41 (Wei et al., 2002) , but are still susceptible to other entry inhibitors such as Vicriviroc and AMD3100 (Ray et al., 2007) , consistent with a synergistic effect between T-20 and AMD3100 in vitro (Tremblay et al., 2000) . Two phase 3 studies, TORO1 and TORO2, showed that at week 24 the T-20 groups exhibit lower mean viral load, greater percentage of patients with less than 50 HIV-1 RNA copies/mL, greater increase in CD4 + cell count and fewer subjects encountering virologic failure as compared with the optimized background regimen alone group (Lalezari et al., 2003; Lazzarin et al., 2003) . Moreover, data collected at week 48 further confirm the safety and efficacy of T-20 in treatment-experienced patients Trottier et al., 2005) . T-20 has successfully been included into other optimized background regimens containing Tipranavir (Cahn et al., 2006; Hicks et al., 2006) , Darunavir (Clotet et al., 2007; Katlama et al., 2007) , Raltegravir and Etravirine Madruga et al., 2007) . Although T-20 is the first HIV entry inhibitor for the treatment of AIDS patients, its preventive use is limited due to its relatively low potency, short half-life inconvenient administration, and rapid induction of drug-resistant virus. T-20 is now mainly provided as a second-line medication for patients with drug resistance to reverse transcriptase inhibitors and protease inhibitors.
Protein & Cell
As one of the new generation of HIV fusion inhibitors, Sifuvirtide is another mimicking peptide of gp41 but contains a pocket-binding domain (PBD) (Fig. 2D) , which is similar to other new fusion inhibitors such as T-1249, T-1144 and CP32M (Eron et al., 2004; He et al., 2008) . Sifuvirtide was designed based on its three-dimensional structure that shares some conformational features with native gp41, resulting in higher binding affinity and potency to block HIV entry (He et al., 2008) . Sifuvirtide can inhibit both CCR5-and CXCR4-tropic HIV-1 infectivity synergistically with T-20. Moreover, T-20 resistant virus retains susceptibility to Sifuvirtide. These observations collectively indicate that these new HIV entry inhibitors have distinct mechanisms of action. Moreover, their combined use with T-20 may improve antiviral potency, pharmacokinetic properties and resistant profiles (Pan et al., 2009) . Clinical phase 1a trials demonstrated that by injection Sifuvirtide is safe and well tolerated in healthy volunteers with potential for further development (He et al., 2008) .
SMALL MOLECULE ENTRY INHIBITORS
In comparison to synthetic peptides, small molecule inhibitors are easier for chemical modification to improve antiviral activity while to reduce toxicity. Another major advantage is that this class of drug is often safe, well tolerated and often orally bio-available. The currently developed small molecule entry inhibitors against HIV-1 are discussed below.
BMS-378806 (Fig. 2E ) and BMS-488043 (Fig. 2F ) inhibit HIV-1 infection by binding gp120, the so-called HIV-1 attachment inhibitors (Lin et al., 2003; Wang et al., 2003; Ho et al., 2006) . They function by entering into the CD4 binding pocket of gp120, inducing conformational changes and blocking the interaction between gp120 and CD4 Ho et al., 2006) . Other studies, however, suggested that these compounds may rather block CD4-induced exposure of gp41 N-terminal heptad repeat (NHR) without affecting CD4 binding or co-receptor binding (Si et al., 2004) . In contrast, two new small molecule CD4 mimics, namely NBD-556 and NBD-557, which indeed bind to the Phe43 pocket of gp120, have been identified (Madani et al., 2008) . They compete with CD4, induce conformational changes in gp120 and enhance co-receptor binding. As for preventive purpose, the combination of BMS-378806 with CCR5 inhibitor and fusion inhibitor in the formulation of microbicide conferred complete protection against vaginal SHIV challenge in rhesus macaques (Veazey et al., 2005) . As compared with BMS-378806, BMS-488043 showed enhanced oral bioavailability and metabolic stability . Moreover, as revealed in a clinical phase 1 trial in healthy volunteers, BMS-488043 is safe and well tolerated (Hanna et al., 2011) . In an 8-day monotherapy conducted in HIV-infected patients, greater mean reduction of viral load was achieved in the BMS-488043-treated group compared to that of the placebo-treated group (Hanna et al., 2011) . Resistant viruses with an amino acid substitution near the CD4 binding pocket were detected in subjects from the BMS-488043-treated group . AMD3100 (JM3100, SID791) is a CXCR4-specific small molecule antagonist with potent anti-CXCR4 tropic HIV-1 activity (Fig. 3A) (De Clercq et al., 1994; Donzella et al., 1998) . It interacts directly with CXCR4 and inhibits SDF-1α induced signaling. It has little oral bioavailability due to the highly charged nature of its bicyclam structure. In vitro selection resulted in AMD3100-resistant virus with variations in V3 loop (De Vreese et al., 1996) . In clinical trials, AMD3100 induced abnormal thrombocytopenia or premature ventricular contraction in 3 of 40 HIV-infected patients (Hendrix et al., 2004) . AMD3100 has been discontinued for the development of antiviral therapy but it was approved as a medication in hematopoietic stem cell mobilization with a commercial name of Mozobil/Plerixafor (DiPersio et al., 2009) .
TAK-779 is the first non-peptide CCR5 antagonist reported with highly potent and specific inhibitory effect against CCR5-tropic HIV-1 infection (Fig. 3B) . It inhibits chemokine binding to CCR5 at nanomolar concentrations (Baba et al., 1999) . Mutagenesis analysis showed that its binding pocket is located within the transmembrane domains (TM) 1, 2, 3 and 7 of CCR5. After TAK-779 binding, CCR5 undergoes a conformational change to become resistant to virus entry (Dragic et al., 2000) . In clinical trials, TAK-779 induces local irritation at injection sites, which prevents this small molecule inhibitor from further development. The quaternary ammonium moiety of TAK-779 prohibits its oral bioavailability. Subsequent modification led to the discoveries of TAK-652 ( Fig. 3C) (Seto et al., 2006) and TAK-220 (Fig. 3D ) Imamura et al., 2006) , of which both are orally available as subnanomolar anti-HIV-1 inhibitors. TAK-652 resistant virus emerged through in vitro selection shows cross-resistance to TAK-779 but remains sensitive to TAK-220 (Baba et al., 2007) . The safety and long half-life of TAK-652 are shown in healthy volunteers (Palleja et al., 2009) . TAK-652 also conferred a substantial reduction in viral load in HIV-infected and treatment-experienced patients in a phase 2 clinical study . TAK-220 inhibited diverse subtypes of CCR5-tropic HIV-1 isolated in vitro . Synergy was observed between TAK-220 and other classes of antiviral medications at high inhibitory concentrations (IC 90 and IC 95 ). Currently, the efficacy and safety of TAK-220 are being investigated in clinical trials .
Maraviroc (UK-427857) is the first US FDA-approved CCR5 antagonist currently used in HAART treatment-experienced patients (Fig. 3E) (Dorr et al., 2005) . The IC 50 value of this drug is at low nanomolar levels against primary CCR5-tropic HIV-1 isolates from various subtypes. Maraviroc inhibits chemokine (MIP-1α, MIP-1β and RANTES) binding to CCR5 in addition to inhibiting chemokine-stimulated signaling without inducing CCR5 internalization (Dorr et al., 2005) . Maraviroc shows no antagonism with other clinically used antiviral agents, such as transcriptase inhibitor, protease inhibitor and fusion inhibitor (Dorr et al., 2005) . The critical amino acids on CCR5 involved in the interaction with Maraviroc are located within the transmembrane domains (Kondru et al., 2008) . Maraviroc drug-resistant variants are selected from some primary viral isolates in vitro, resulting from either a tropism shift to CXCR4 or an adaptation to utilize Maraviroc-bound CCR5 (Westby et al., 2007) . Amino acid substitutions in V3 loop contributed to both of the two types of resistances (Westby et al., 2007) . In phase 3 clinical trials (MOTIVATE 1 & 2), randomly assigned patients, who had exclusively CCR5-tropic HIV-1, received 300 mg Maraviroc once or twice daily or placebo, together with an optimized background regimen. In combined analysis, the mean reduction of viral load at week 48 was 0.9-and 1.05-log10 copies/mL greater in Maraviroc once and twice daily groups, respectively, than that in placebo group, together with higher frequencies of patients whose viral load had been suppressed to less than 50 copies/mL and of CD4 + count increase (Fatkenheuer et al., 2008; Gulick et al., 2008) . In another phase 3 clinical trial (MERIT), treatment-naïve patients were recruited and the efficacy and safey of Maraviroc as a first-line regimen were investigated. At week 48, a similar proportion of patients with less than 50 copies HIV RNA/mL was achieved in the Maraviroc-treated group, as compare with that in the Efavirenz group (a reverse transcriptase inhibitor), but CD4 + cell count rebound was greater in patients received Maraviroc (Cooper et al., 2010) . These observations were confirmed by week 96 analysis (Hardy et al., 2010; Sierra-Madero et al., 2010) . The emergence of pre-existing CXCR4-tropic HIV-1 that failed to be detected in pre-treatment screening was related to virologic failure (Fatkenheuer et al., 2008; Cooper et al., 2010) . CCR5-tropic Maraviroc-resistant strains have also been reported (Fatkenheuer et al., 2008) , and the in vivo acquisition of Maraviroc-resistance was also a result of V3 sequence changes, similar to that from in vitro selection (Tilton et al., 2010 (Fig. 3F ) . It has broad-spectrum inhibitory activity against diverse lab-adapted or clinically-isolated CCR5-tropic HIV-1 strains at sub-nanomolar concentrations. Like Maraviroc, Vicriviroc also blocks chemokine binding to CCR5 and subsequent signaling. Synergistic effect was observed when Vicriviroc was combined with other antiviral drugs . Escape variants under the selection pressure of vicriviroc did not switch to CXCR4 tropism but evolved mutations in fusion peptide region of gp41 (Marozsan et al., 2005; Berro et al., 2009) . In a phase 2 clinical trial (VICTOR-E), randomized treatment-experienced subjects receiving 20 mg of Vicriviroc once daily had a significantly greater mean reduction in viral load from the baseline as well as a significantly better recovery of mean CD4 + cell count than those receiving placebo at week 48 (Suleiman et al., 2010 ). Another phase 2 trial (ACTG A5211) piloted in treatment-experienced patients showed that during a period of 24 weeks, fewer subjects from the Vicriviroc arms experienced virologic failure than those from the placebo arm (Crawford et al., 2010) . This result was further supported by a 48 weeks follow-up study. Up to 3 years, 49% of patients achieving a viral load of less than 50 copies/mL within 24 weeks did not encounter viral rebound (Wilkin et al., 2010) . Unexpectedly, two phase 3 studies (VICTOR-E3 and E4) did not reach statistically significant difference in protective efficacy between the Vicriviroc and placebo groups, forcing the discontinuation to seek for FDA's approval (Gathe et al., 2010) . Aplaviroc (GW873140, ONO4128, AK602) is another noncompetitive, CCR5 specific antagonist (Fig. 3G) . It exhibits potent antiviral activity at subnanomolar EC 50 against diverse CCR5 tropic HIV-1 (Maeda et al., 2004) . It inhibits the recognition of MIP-1α but not of MIP-1β and RANTES. Chemokine-induced CCR5 signaling is also blocked by Aplaviroc (Maeda et al., 2004) . Co-administration of Aplaviroc with other CCR5 allosteric inhibitors in blocking MIP-1α binding showed an antagonistic effect, indicating that they may share a common site of action on CCR5 (Watson et al., 2005) . Synergistic anti-HIV-1 activity was observed in the combination of Aplaviroc with reverse transcriptase inhibitors and T-20 (Nakata et al., 2008) . In a short-term monotherapy for HIV-1 infected patients, Aplaviroc was well tolerated and provided a robust reduction of viremia . However, phase 2b/3 clinical trials (ASCENT and EPIC) were halted due to the severe hepatotoxicity in some subjects (Nichols et al., 2008) .
TD-0680 is a recently discovered CCR5 antagonist (Fig.  3H) . It displays the greatest potency against a diverse group of R5-tropic HIV-1 and SIV strains when compared to its prodrug TD-0232, the FDA-approved CCR5 antagonist Maraviroc, and TAK-779 with EC 50 values in the subnanomolar range (0.09-2.29 nmol/L) . It is equally potent at blocking envelope-mediated cell-to-cell fusion, cell-mediated viral transmission, as well as the replication of a TAK-779/Maraviroc-resistant HIV-1 variant. This drug may offer an advantage over a potent CD4bs directed neutralizing antibody that was inefficient to block cell-mediated viral transmission (Abela et al., 2012) . Interestingly, TD-0232 and TD-0680 function differently despite binding to a similar transmembrane (TM) pocket of CCR5. Site-directed mutagenesis, drug combination and antibody blocking assays have revealed a novel mechanism of action of TD-0680. Besides binding to the TM pocket, the unique exo-configuration of TD-0680 protrudes and sterically blocks access to the ECL-2 region of CCR5, thereby interrupting the interaction between virus and its co-receptor more effectively . TD-0680, therefore, merits development as an anti-HIV-1 agent for therapeutic purposes or as a topical microbicide for the prevention of sexual transmission of R5-tropic HIV-1. In addition, since TD-0680 also blocks rhesus CCR5 effectively, it makes it possible to be tested in macaque models for efficacy evaluation (Chen et al., 1997; Kang et al., 2012) .
GENE THERAPIES
With the rapid progress of gene engineering, targeted gene manipulation technology has become more and more attractive for illness treatment, including HIV-1 infection. This trend is boosted by developed applications of restriction endoclease, RNA inference (RNAi) and induced pluripotent stem cell (iPSC). Despite of the safety and ethical issues, gene therapy remains a promising targeted intervention method against HIV-1 transmission.
Zinc-finger nuclease (ZFN) is an engineered restriction endonuclease comprising a zinc-finger protein DNA-binding domain and a DNA-cleavage domain (Urnov et al., 2005) . The specific disruption of the genomic sequence around a target site is determined by the specific assembly of zinc-finger motifs in the DNA-binding domain. The significance of genome editing by ZFN is that its transient expression can result in permanent gene disruption (Urnov et al., 2005) . The fact that individuals with homozygous CCR5∆32 and red-capped mangabeys with homozygous CCR5∆24 deletions are apparently normal but protected against CCR5-tropic viral infections makes CCR5 a preferential target for gene depletion Chen et al., 1998) . Recently, CCR5-specific ZFNs disrupt endogenous CCR5 in primary CD4 + T cells, providing a robust and stable protection against HIV-1 infection both in vitro and in vivo (Perez et al., 2008) . The ZFN-treated CD4 + T cells can be enriched after CCR5-tropic HIV-1 infection and remain susceptible to CXCR4-tropic virus. Critically, mice engrafted with CCR5 ZFN-treated human CD4 + T cell have a significantly lower viral load post HIV-1 infection, further suggesting its efficacy (Perez et al., 2008) . A phase 1 clinical study of this gene therapy conducted in HIV-infected patients showed a rebound of CD4 + T cell count in 5 of 6 subjects (Tebas et al., 2011) . CCR5-specific ZFN also induces disruption of CCR5 in CD34 + human hematopoietic stem/progenitor cells (HSPCs) (Holt et al., 2010) . The ZFN-treated CD34 + HSPCs preserve the capability of multi-lineage engraftment. Mice transplanted with CCR5 ZFN-modified HSPCs retain normal human cell profiles in peripheral blood and various tissues, and are able to control viral replication after HIV-1 challenge (Holt et al., 2010) . These findings are supported by the long-term viral control of a HIV-infected leukemia patient (Hutter et al., 2009 ). This patient who received CCR5 homozygous ∆32 deletion stem-cells from a HLA-matched donor had an undetectable level of viremia up to 20 months post the procedure, suggesting a possible cure of HIV-1 infection (Hutter et al., 2009 ). In addition, CXCR4-specific ZFN-mediated CXCR4 depletion confers human CD4 + T cell resistance against CXCR4-tropic HIV-1 (Wilen et al., 2011) . It is possible that the combination of gene silencing and hematopoietic stem cell (HSC) transplantation may be a promising therapeutic cure for HIV-infected patients. Interestingly, after transduction with lhx2, iPSCs differentiated robustly to HSC-like cells, which retained multi-lineage differentiation ability after being transferred to mouse model (Kitajima et al., 2011) . This technique potentially circumvents the severe issues of graft-versus-host disease and immune rejection, which are common complications of allogeneic transplantation. Therefore, manipulation of stem cells viable for ZFN-mediated therapy could be developed. RNAi has been known as a powerful tool to suppress specific protein expression in a posttranscriptional manner (Mello and Conte, 2004) . Co-receptor-specific siRNA leads to cell resistance to HIV-1 in vitro using either conventional lentivirus or non-viral system as delivery vectors (Anderson et al., 2009 ). CD4-specific siRNA also protects target cells from HIV-1 infection (Martinez et al., 2002) . Moreover, in vivo delivery of CCR5-specific siRNA effectively inhibits viral replication in both hu-PBL and humanized HSC mice (Kumar et al., 2008) . Transplantation of anti-CCR5 siRNA modified CD34 + HPSCs into humanized mice stably down-regulates CCR5 expression in systemic lymphoid organs and contributes to inhibition against HIV-1 (Shimizu et al., 2010) . In a combination gene therapy, siRNA together with chimeric TRIM5α and a TAR decoy, provided target cells with complete protection without inducing any escape viruses, further illustrating its potential therapeutic use (Anderson et al., 2009) . Through a genome-wide screen by siRNA library, some novel targets in protein transport machinery have been identified to be essential for HIV-1 entry (Brass et al., 2008) . Rab6 and Vps53 are believed to be essential for the retrograde traffic from endosome to trans-Golgi network (Conibear and Stevens, 2000; Del Nery et al., 2006) . Depletion of Rab6 and Vps53 by stably expressed short hairpin RNA (shRNA) results in resistance to HIV-1 at the entry phase without altering surface CD4 and co-receptor expression (Brass et al., 2008) . The genomic screening, therefore, may provide us with more alternative targets to block HIV-1 entry.
PERSPECTIVES
The ultimate solution for HIV-1 prevention relies on the development of an effective vaccine. Since such a vaccine remains elusive after 30 years of efforts, HIV-1 has likely evolved in a way to avoid the generation of timely potent bnAbs so that the persistent and latent infection can be firmly established. Meantime, immunogen design based on isolated viruses has repeatedly failed to elicit potent bnAbs, suggesting that infection per se is not the reason underlying the disappointing vaccination. Understanding how bnAbs are induced in patients during the natural course of infection has, therefore, become one of the priorities in the area of HIV-1 vaccine research. To this end, significant progresses have been made in recent years by identifying several novel potent bnAbs from a small fraction of naturally infected individuals, who developed potent neutralizing sera. On one hand, the structural analysis of these bnAbs in complex with bound HIV-1 antigen may shed light on new vaccine design although this so-called "retro-vaccinololgy" approach has yet resulted in an effective vaccine. On the other hand, using the newly identified bnAbs via passive immunization is likely a practical strategy for HIV-1 prevention, which is one of the key messages of this review. Non-vaccine strategies in targeting viral entry phase should have critical implications for HIV-1 prevention.
Despite the astonishing diversity of HIV-1 and its devious strategy to evade the immune system, about 8%-25% infected individuals do develop bnAbs naturally after 1-3 years of infection. Based on B cell genome and bnAb structural analyses, however, most bnAbs harbor a long CDR H3 region and unusual somatic mutations over the course of bnAb-secreting B cell maturation. Currently, due to the lack of a proper animal model to study human B cell maturation and the induction of long CDR H3 bnAbs, it is possible that using active vaccination to elicit potent bnAbs may take years if not decades to fulfill. In contrast, passive immunization by combining recently discovered bnAbs may achieve theoretically maximal neutralization coverage against an extremely large proportion of HIV-1 isolates at a low but effective concentration. It is, therefore, conceivable that some of passive immunization strategies may benefit human populations before an effective vaccine becomes available. Necessary resources should be made available to support such evidence-based (e.g. demonstrated efficacy in SHIV/macaque models) research and developmental plans, and to promote the discoveries of effective bnAb delivery system and of optimized long-half life bnAbs.
Besides passive immunization using bnAbs, other non-vaccine strategies targeting viral entry should also be explored for HIV-1 prevention. These strategies may include the use of synthesized peptides and polymers, small molecule entry inhibitors and even gene therapies, or their combined application as indicated in this review. Although it is and Hong Kong AIDS Trust Fund MSS183R, by the University Development Fund and LKSFM Matching Fund of the University of Hong Kong to AIDS Institute and by the National Science and Technology Major Project 2012ZX10001-009. The authors declare no conflict of interest.
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